Resverlogix (TSX:RVX, StockForum), a Calgary-based clinical stage cardiovascular company developing compounds involving a therapeutic increase in ApoA-I, announced today that the company's BET protein binder, RVX-208, was recognized in two different industry publications for its unique properties.
The publication, entitled “RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist”, was released December 31st in an international peer-reviewed online publication, PLOS ONE Journal. The piece was a collaboration between Resverlogix staff and Maryland-based Xtal Biostructures.
Earlier in October, the Structural Genomics Consortium, along with a collection of University of Oxford UK scientists, published “RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.”
Resverlogix president and CEO, Donald J. McCaffrey, commented, “The Structural Genome - Oxford paper was viewed by us as an extremely important publication as it confirmed by an external group for the first time that RVX-208 was the first known selective BET inhibitor thus highlighting Resverlogix' technological lead in the bromodomain space.”
Back in August, the Cell Journal ran a piece entitled “BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure”, noting that RVX-208 is a BET inhibitor with potential as a therapeutic target in heart failure. The authors were mainly from different divisions of Harvard Medical School.
According to the news release, RVX-208 is a small-molecule in development for the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease.
Resverlogix was in the news recently when the company completed enrollment of Phase 2 clinical trials of RVX-208 in patients with pre-Diabetes Mellitus.
Shares rose 15.46% on the news to $0.56 per share.
Currently there are 81.7m outstanding shares with a market cap of $45.8 million.